[Skip to Content]
[Skip to Content Landing]
October 11, 2000

Stent Scrutiny

Author Affiliations

Author Affiliations: Department of Cardiology and Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Foundation, Cleveland, Ohio.

JAMA. 2000;284(14):1839-1841. doi:10.1001/jama.284.14.1839

Since the inception of balloon angioplasty in the early 1980s, the field of interventional cardiology has enjoyed explosive growth. It is estimated that more than 1.3 million percutaneous coronary revascularization procedures were performed worldwide in 1999, considerably more than the approximately 700,000 coronary artery bypass graft operations.1 Important limitations of balloon angioplasty, however, include the risk of uncontrolled plaque disruption, leading to periprocedural coronary occlusion and myocardial infarction, and a 20% to 40% incidence of recurrent narrowing (restenosis) during the 6 to 12 months following successful revascularization.2 A variety of new technologies have been developed to overcome these limitations, the most successful of which has been the coronary stent.

First Page Preview View Large
First page PDF preview
First page PDF preview